<p>在過去的 7 天裏，美國市場上漲了 2.7%，過去一年上漲了 13%，預計未來幾年盈利將年增長 15%。在這種情況下，投資者可能會發現低價股的價值——通常是較小或較新的公司——當其背靠強大的財務健康時，可以提供增長機會。儘管今天被視為一個小眾領域，低價股仍然對那些尋求潛在隱藏價值和長期收益的人具有相關性；在這裏，我們探討三隻結合了資產負債表韌性與良好前景的股票。</p>
<h3>美國十大低價股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國低價股篩選器的 449 只股票的完整列表。</p>
<p>下面我們展示了一些通過我們的篩選器篩選出的股票。</p>
<h2>Nautilus Biotechnology (NAUT)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家開發階段的生命科學公司，專注於創建一種平台技術，以量化和解鎖蛋白質組的複雜性，市值約為 1.009 億美元。</p>
<p><strong>運營：</strong> Nautilus Biotechnology 尚未報告任何收入細分。</p>
<p><strong>市值：</strong> $100.09M</p>
<p>Nautilus Biotechnology 的市值為 1.009 億美元，是一家面臨低價股典型挑戰的無收入生命科學公司。它最近收到了納斯達克的通知，因未滿足最低出價要求，但有直到 2025 年 10 月 28 日的時間來恢復合規。儘管沒有債務且短期資產顯著超過負債（1.416 億美元對比 3330 萬美元），但公司仍然處於虧損狀態，五年內虧損年增長率為 20.5%，且近期沒有盈利預測。預計收入將大幅增長，但預計三年內盈利將年下降 8.5%。</p>
<ul>
<li>點擊這裏查看完整的健康分析報告，以深入瞭解 Nautilus Biotechnology。</li>
<li>通過我們的詳細增長報告評估 Nautilus Biotechnology 的未來盈利預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT 債務與股本歷史及分析截至 2025 年 6 月</p>
<h2>BARK (BARK)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BARK, Inc. 是一家以狗為中心的公司，提供狗的產品、服務和內容，市值約為 1.445 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自兩個主要細分市場：商業，產生 6835 萬美元，以及直接面向消費者，貢獻 4158.4 萬美元。</p>
<p><strong>市值：</strong> $144.5M</p>
<p>BARK, Inc.的市值為 1.445 億美元，專注於以狗為中心的產品和服務，正在應對低價股典型的挑戰。儘管處於虧損狀態，並且預計在未來三年內不會實現盈利，但 BARK 顯示出財務改善；其短期資產顯著超過短期和長期負債。最近的收益顯示，截止 2025 年 3 月 31 日的年度銷售額略微下降至 4.8418 億美元，而虧損相比去年有所縮小。由於宏觀環境不確定，公司預計第一季度收入將下降，原因是減少了市場營銷投入。</p>
<ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解 BARK 的動態。</li>
<li>在這裏瞭解 BARK 的未來增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown"/></p>
<p>BARK 收入與支出細分截至 2025 年 6 月</p>
<h2>Seritage Growth Properties (SRG)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Seritage Growth Properties 是一家專注於美國各地多元化零售和混合用途物業的擁有、開發、重建、管理、銷售和租賃的公司，市值約為 1.6559 億美元。</p>
<p><strong>運營：</strong> 公司的收入細分主要涉及房地產物業，產生-341 萬美元。</p>
<p><strong>市值：</strong> $165.59M</p>
<p>Seritage Growth Properties 的市值為 1.6559 億美元，正在應對房地產領域低價股的複雜性。儘管持續虧損且五年內盈利下降，其 1.231 億美元的短期資產顯著超過短期負債，但與 2.4 億美元的長期負債相比則顯得不足。公司在五年內將債務從 157.9% 減少至 62.8%，並最近對其定期貸款設施進行了自願提前還款，自 2021 年 12 月以來每年減少約 9940 萬美元的利息支出，同時追求戰略性銷售計劃，將其資產組合從大約 160 個減少至 15 個，自 2022 年 3 月以來。</p>
<ul>
<li>點擊查看我們在 Seritage Growth Properties 財務健康報告中的詳細分析。</li>
<li>查看我們的歷史業績報告，以獲取 Seritage Growth Properties 的業績記錄的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis"/></p>
<p>截至 2025 年 6 月的 SRG 財務狀況分析</p>
<h2>總結</h2>
<ul>
<li>在這裏調查我們完整的 449 只美國便士股票。</li>
<li>對其他可能性感興趣？通過提供可靠收入來源的穩健分紅股票來多樣化您的投資組合，以應對潛在的市場動盪。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

NAUT

<p>Nautilus Biotechnology 被認為是一個頂級的便士股票，儘管面臨挑戰，包括因未滿足競標價格要求而收到納斯達克的通知。其市值為 1.0009 億美元，仍處於虧損狀態，虧損每年增加。過去一週，美國市場上漲了 2.7%，過去一年上漲了 13%，這引發了對便士股票的興趣，期待其潛在增長。其他值得注意的便士股票包括 BARK, Inc. 和 Seritage Growth Properties，它們在各自領域中也面臨類似的挑戰</p>

<p>Over the last 7 days, the United States market has risen by 2.7%, and over the past year, it is up by 13%, with earnings expected to grow annually by 15% in the coming years. In light of these conditions, investors might find value in penny stocks—typically smaller or newer companies—that can offer growth opportunities when backed by strong financial health. Though considered a niche area today, penny stocks remain relevant for those seeking potential hidden value and long-term gains; here we explore three such stocks that combine balance sheet resilience with promising prospects.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場上漲了 2.7%，過去一年上漲了 13%，預計未來幾年盈利將年增長 15%。在這種情況下，投資者可能會發現低價股的價值——通常是較小或較新的公司——當其背靠強大的財務健康時，可以提供增長機會。儘管今天被視為一個小眾領域，低價股仍然對那些尋求潛在隱藏價值和長期收益的人具有相關性；在這裏，我們探討三隻結合了資產負債表韌性與良好前景的股票。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大低價股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 449 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國低價股篩選器的 449 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些通過我們的篩選器篩選出的股票。</p>
</div><h2>Nautilus Biotechnology (NAUT)</h2>
<div class="lb-trans"><h2>Nautilus Biotechnology (NAUT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome, with a market cap of approximately $100.09 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家開發階段的生命科學公司，專注於創建一種平台技術，以量化和解鎖蛋白質組的複雜性，市值約為 1.009 億美元。</p>
</div><p><strong>Operations:</strong> Nautilus Biotechnology has not reported any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Nautilus Biotechnology 尚未報告任何收入細分。</p>
</div><p><strong>Market Cap:</strong> $100.09M</p>
<div class="lb-trans"><p><strong>市值：</strong> $100.09M</p>
</div><p>Nautilus Biotechnology, with a market cap of US$100.09 million, is a pre-revenue life sciences company facing challenges typical of penny stocks. It recently received notice from Nasdaq for not meeting the minimum bid price requirement but has until October 28, 2025, to regain compliance. Despite being debt-free and having short-term assets exceeding liabilities significantly (US$141.6 million vs. US$33.3 million), the company remains unprofitable with losses increasing at an annual rate of 20.5% over five years and no profitability forecast in the near term. Revenue is expected to grow substantially, yet earnings are projected to decline by 8.5% annually over three years.</p>
<div class="lb-trans"><p>Nautilus Biotechnology 的市值為 1.009 億美元，是一家面臨低價股典型挑戰的無收入生命科學公司。它最近收到了納斯達克的通知，因未滿足最低出價要求，但有直到 2025 年 10 月 28 日的時間來恢復合規。儘管沒有債務且短期資產顯著超過負債（1.416 億美元對比 3330 萬美元），但公司仍然處於虧損狀態，五年內虧損年增長率為 20.5%，且近期沒有盈利預測。預計收入將大幅增長，但預計三年內盈利將年下降 8.5%。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Nautilus Biotechnology.</li>
<li>Assess Nautilus Biotechnology's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏查看完整的健康分析報告，以深入瞭解 Nautilus Biotechnology。</li>
<li>通過我們的詳細增長報告評估 Nautilus Biotechnology 的未來盈利預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>NAUT 債務與股本歷史及分析截至 2025 年 6 月</p>
</div><h2>BARK (BARK)</h2>
<div class="lb-trans"><h2>BARK (BARK)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BARK, Inc. is a dog-centric company offering products, services, and content for dogs with a market cap of approximately $144.50 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> BARK, Inc. 是一家以狗為中心的公司，提供狗的產品、服務和內容，市值約為 1.445 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from two primary segments: Commerce, which generated $68.35 million, and Direct to Consumer, contributing $415.84 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自兩個主要細分市場：商業，產生 6835 萬美元，以及直接面向消費者，貢獻 4158.4 萬美元。</p>
</div><p><strong>Market Cap:</strong> $144.5M</p>
<div class="lb-trans"><p><strong>市值：</strong> $144.5M</p>
</div><p>BARK, Inc., with a market cap of US$144.50 million, is navigating the challenges typical of penny stocks with a focus on dog-centric products and services. Despite being unprofitable and not expected to achieve profitability in the next three years, BARK has shown financial improvements; its short-term assets exceed both short-term and long-term liabilities significantly. Recent earnings revealed a slight decline in sales to US$484.18 million for the year ended March 31, 2025, while losses have narrowed compared to the previous year. The company anticipates lower first-quarter revenue due to reduced marketing efforts amid uncertain macro conditions.</p>
<div class="lb-trans"><p>BARK, Inc.的市值為 1.445 億美元，專注於以狗為中心的產品和服務，正在應對低價股典型的挑戰。儘管處於虧損狀態，並且預計在未來三年內不會實現盈利，但 BARK 顯示出財務改善；其短期資產顯著超過短期和長期負債。最近的收益顯示，截止 2025 年 3 月 31 日的年度銷售額略微下降至 4.8418 億美元，而虧損相比去年有所縮小。由於宏觀環境不確定，公司預計第一季度收入將下降，原因是減少了市場營銷投入。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of BARK.</li>
<li>Learn about BARK's future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解 BARK 的動態。</li>
<li>在這裏瞭解 BARK 的未來增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown"/></p>
<p>BARK Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>BARK 收入與支出細分截至 2025 年 6 月</p>
</div><h2>Seritage Growth Properties (SRG)</h2>
<div class="lb-trans"><h2>Seritage Growth Properties (SRG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Seritage Growth Properties is a company focused on the ownership, development, redevelopment, management, sale and leasing of diversified retail and mixed-use properties across the United States with a market cap of approximately $165.59 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Seritage Growth Properties 是一家專注於美國各地多元化零售和混合用途物業的擁有、開發、重建、管理、銷售和租賃的公司，市值約為 1.6559 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment primarily involves real estate properties, which generated -$3.41 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入細分主要涉及房地產物業，產生-341 萬美元。</p>
</div><p><strong>Market Cap:</strong> $165.59M</p>
<div class="lb-trans"><p><strong>市值：</strong> $165.59M</p>
</div><p>Seritage Growth Properties, with a market cap of US$165.59 million, is navigating the complexities of penny stocks in the real estate sector. Despite ongoing unprofitability and declining earnings over five years, its short-term assets of US$123.1 million exceed short-term liabilities significantly but fall short against long-term liabilities of US$240 million. The company has reduced its debt substantially from 157.9% to 62.8% over five years and recently made a voluntary prepayment on its term loan facility, reducing annual interest expenses by approximately US$99.4 million since December 2021 while pursuing a strategic Plan of Sale reducing its portfolio to 15 assets from approximately 160 since March 2022.</p>
<div class="lb-trans"><p>Seritage Growth Properties 的市值為 1.6559 億美元，正在應對房地產領域低價股的複雜性。儘管持續虧損且五年內盈利下降，其 1.231 億美元的短期資產顯著超過短期負債，但與 2.4 億美元的長期負債相比則顯得不足。公司在五年內將債務從 157.9% 減少至 62.8%，並最近對其定期貸款設施進行了自願提前還款，自 2021 年 12 月以來每年減少約 9940 萬美元的利息支出，同時追求戰略性銷售計劃，將其資產組合從大約 160 個減少至 15 個，自 2022 年 3 月以來。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Seritage Growth Properties' financial health report.</li>
<li>Review our historical performance report to gain insights into Seritage Growth Properties' track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊查看我們在 Seritage Growth Properties 財務健康報告中的詳細分析。</li>
<li>查看我們的歷史業績報告，以獲取 Seritage Growth Properties 的業績記錄的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis"/></p>
<p>SRG Financial Position Analysis as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SRG 財務狀況分析</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Investigate our full lineup of 449 US Penny Stocks right here.</li>
<li>Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏調查我們完整的 449 只美國便士股票。</li>
<li>對其他可能性感興趣？通過提供可靠收入來源的穩健分紅股票來多樣化您的投資組合，以應對潛在的市場動盪。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

Nautilus Biotechnology 在我們評選的前三名便士股票中名列前茅